Nearly all neuromyelitis optica spectrum disorder patients on Enspryng remain free from relapses after six months, a real-world study in Japan shows.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
In patients treated with Enspryng, researchers found the proportions of B-cells was unchanged, suggesting it altered their characteristics.| Neuromyelitis News